Triple-negative breast cancer (TNBC) is more aggressive, has limited current treatment options, and has a poor clinical prognosis once metastasis occurs. Platinum-based drugs have a broad antitumor spectrum and better efficacy, but are associated with greater adverse effects.
Multiple studies have found that platinum-containing regimens show better results in triple-negative breast cancer, improving the proportion of complete pathological remissions after neoadjuvant therapy, that is, making more breast cancer patients’ cancer cells disappear under the microscope. However, it is not yet possible to demonstrate whether platinum-containing regimens can delay disease progression and prolong survival, i.e., it is not clear whether the addition of platinum-based agents provides a survival benefit in triple-negative breast cancer, and more studies are needed to explore and validate this. In general, achieving pathologic complete remission is meaningful for oncologic treatment and has the potential to prolong survival, but there is also the undeniable possibility of simply boosting the rate of pathologic complete remission without improving survival.
In conclusion, for triple-negative breast cancer, adding platinum-based therapy to conventional chemotherapy is not a standard treatment option, but given the enhanced pathologic remission rate with the addition of platinum, consider participating in appropriate clinical trials or taking professional advice from your physician.